Navigation Links
Treatment resistance in some cancer cells may be reversible
Date:4/1/2010

The ability of cancer cells to resist treatment with either targeted drug therapies or traditional chemotherapy may, in some cases, result from a transient state of reversible drug "tolerance." In a paper that will appear in the journal Cell and is receiving early online release, researchers from the Massachusetts General Hospital (MGH) Cancer Center report finding small populations of drug-tolerant cells from several different types of tumors and identifying aspects of the underlying mechanism.

"While resistance to cancer drugs can result from rare, pre-existing genetic mutations that emerge in response to treatment, accumulating evidence has pointed to additional nongenetic, potentially reversible mechanisms," says Jeffrey Settleman, PhD, of the MGH Cancer Center, who led the study. "In cell lines derived from several different types of cancer we found subpopulations of cells that display a transient ability to tolerate exposure to toxic drugs, which was associated with structural changes in the cells' DNA and points to a therapeutic strategy that could potentially prevent resistance from developing."

When cells within a tumor that had responded to treatment resume uncontrolled growth, drug therapy is usually stopped. But there have been many reports indicating that some tumors can regain sensitivity to the previously ineffective treatment after a "drug holiday." In order to investigate the mechanism underlying that phenomenon, the researchers tested several tumor-derived cell lines against drugs to which the original tumors were known to be sensitive.

In each of the lines they examined, a small number of tumor cells survived exposure to concentrations of drug 100 times greater than levels that killed the vast majority of the cells. But when these drug-tolerant cells were placed in an environment without the drug, their offspring eventually regained sensitivity to the drug.

Further investigation revealed that drug tolerance was associated with changes in gene expression, implicating alterations in chromatin, the chromosome structure consisting of DNA wrapped around a protein scaffolding. The researchers found that a particular chromatin-modifying enzyme was required for the development of tolerance, and while no currently available drug inhibits that protein, agents that block an associated group of enzymes did cause the death of drug-tolerant but not drug-sensitive cells.

"We believe this kind of reversible drug resistance may be a fundamental property of many tumor cell populations," says Settleman. "Determining whether what we see in cell cultures will translate into what happens in patients is essential, and we've already started a clinical trial to see if combining a chromatin-modifying agent with the targeted lung-cancer drug erlotinib [Tarceva] may prevent or delay the development of resistance. We're also using our cell culture models to further explore the underlying mechanisms." Settleman is the Laurel Schwartz Professor of Medicine at Harvard Medical School.


'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Steroids May Be Overrated in Treatment of COPD
2. Experimental stem cell treatment arrests acute lung injury in mice, study shows
3. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
4. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
5. New York City Surgeon Develops All-Natural Treatment for Wrinkles and Scars
6. Novelty lures rats from cocaine-paired settings, hinting at new treatments for recovering addicts
7. Northeast Chiropractic, PC Revolutionizes Pain Management Without Medication, Now Offering New and Unique Blend of Treatments
8. Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments
9. Biomarker could help doctors tailor treatment for rheumatoid arthritis
10. St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh
11. Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and beyond ... strives to better communities around the world by offering the Gensuite team and ... opportunity for team members to become involved in a cause that is bigger ...
(Date:1/15/2017)... Rosa, CA (PRWEB) , ... January 15, 2017 ... ... nominate their choice of best physicians in eight Bay Area counties for 2017. ... by the healthcare research company managing the award process. Results were announced the ...
(Date:1/14/2017)... Minneapolis, MN (PRWEB) , ... January 14, 2017 ... ... to present the distinctions among their expanding line of activated charcoal products. With ... emphasizes the importance of categorizing their products according to how they cater to ...
(Date:1/13/2017)... ... 2017 , ... People with type 2 diabetes know to ... as checking the nutrition label on foods for grams of sugar. But carbohydrates ... proteins can influence — either positively or negatively — insulin secretion and glucose ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public ... of providing additional organic alternatives for customers who have grown more conscious about ... line of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... SAN FRANCISCO, Calif. , Jan. 16, 2017 /PRNewswire/ ... that on January 3, 2017 and January 16, 2017 ... the grant of inducement stock options to purchase an ... new employees. These awards were granted pursuant to the ... inducement material to the new employees entering into employment ...
(Date:1/16/2017)... Colo. , Jan. 16, 2017 CBDRx, ... donate large amounts of phyto-nutrient rich hemp extract to ... the donation of their proprietary hemp extract to Veteran,s ... CBDRx the best hemp company in the world and ... best, most nutritious, full spectrum phyto-nutrient rich hemp extract ...
(Date:1/15/2017)... -- Le conseil d,administration de SurgaColl Technologies Ltd., ... la régénération de tissus humains, annonce la nomination de ... effet immédiat. ... Bill est un dirigeant expérimenté à l,international dans l,industrie ... générale et de direction au sein de sociétés internationales spécialisées ...
Breaking Medicine Technology: